307 related articles for article (PubMed ID: 27102266)
1. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.
Christlieb SB; Strandholdt CN; Olsen BB; Mylam KJ; Larsen TS; Nielsen AL; Rohde M; Gerke O; Olsen KE; Møller MB; Kristensen BW; Abildgaard N; Alavi A; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1824-36. PubMed ID: 27102266
[TBL] [Abstract][Full Text] [Related]
2. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.
Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J
Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
5. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer.
Higashi T; Saga T; Nakamoto Y; Ishimori T; Mamede MH; Wada M; Doi R; Hosotani R; Imamura M; Konishi J
J Nucl Med; 2002 Feb; 43(2):173-80. PubMed ID: 11850481
[TBL] [Abstract][Full Text] [Related]
6. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
7. Does dual-time-point
Wu B; Zhao Y; Zhang Y; Tan H; Shi H
Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
[TBL] [Abstract][Full Text] [Related]
8. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas.
Yamada T; Uchida M; Kwang-Lee K; Kitamura N; Yoshimura T; Sasabe E; Yamamoto T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):464-71. PubMed ID: 22676927
[TBL] [Abstract][Full Text] [Related]
9. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
[TBL] [Abstract][Full Text] [Related]
10. Can semiquantitative measurements of SUVmax and cut-off values differentiate colorectal malignant from benign lessions?
Nguyen T; Hess S; Petersen H; Alavi A; Høilund-Carlsen PF
Hell J Nucl Med; 2017; 20(2):113-121. PubMed ID: 28697187
[TBL] [Abstract][Full Text] [Related]
11. ¹⁸FDG PET for grading malignancy in thymic epithelial tumors: significant differences in ¹⁸FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: preliminary study.
Nakajo M; Kajiya Y; Tani A; Yoneda S; Shirahama H; Higashi M; Nakajo M
Eur J Radiol; 2012 Jan; 81(1):146-51. PubMed ID: 20810231
[TBL] [Abstract][Full Text] [Related]
12. Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer.
Baun C; Falch K; Gerke O; Hansen J; Nguyen T; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
BMC Med Imaging; 2018 May; 18(1):11. PubMed ID: 29743027
[TBL] [Abstract][Full Text] [Related]
13. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma.
Park SG; Lee JH; Lee WA; Han KM
Nucl Med Biol; 2012 Nov; 39(8):1167-72. PubMed ID: 22901702
[TBL] [Abstract][Full Text] [Related]
14. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
15. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
16. Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.
Nicolau C; Sala E; Kumar A; Goldman DA; Schoder H; Hricak H; Vargas HA
AJR Am J Roentgenol; 2017 Apr; 208(4):849-853. PubMed ID: 28095016
[TBL] [Abstract][Full Text] [Related]
17. Assessment of FDG retention differences between the FDG-avid benign pulmonary lesion and primary lung cancer using dual-time-point FDG-PET imaging.
Kaneko K; Sadashima E; Irie K; Hayashi A; Masunari S; Yoshida T; Omagari J
Ann Nucl Med; 2013 May; 27(4):392-9. PubMed ID: 23417225
[TBL] [Abstract][Full Text] [Related]
18. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
19. Linked Hexokinase and Glucose-6-Phosphatase Activities Reflect Grade of Ovarian Malignancy.
Olsen BB; Gjedde A; Vilstrup MH; Johnsen IBG; Neumann G; Torigian DA; Alavi A; Høilund-Carlsen PF
Mol Imaging Biol; 2019 Apr; 21(2):375-381. PubMed ID: 29987620
[TBL] [Abstract][Full Text] [Related]
20. Physiological uptake values of 18F-FDG in long bones of the lower extremity on PET/CT imaging.
van Vliet KE; van Eck-Smit BL; de Jong VM; Goslings JC; Schep NW; Termaat MF
Nucl Med Commun; 2016 Jun; 37(6):589-92. PubMed ID: 26849073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
